{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:39:58Z","timestamp":1793507998456,"version":"4.5.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged \u226512 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>A literature search was conducted through October 2025 using PubMed and ClinicalTrials.gov with the terms \u201clebrikizumab,\u201d \u201cEbglyss,\u201d \u201clebrikizumab clinical trials,\u201d and \u201clebrikizumab atopic dermatitis.\u201d Phase I to III clinical trials, post-approval studies, and FDA package insert were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Trials evaluating lebrikizumab in patients with AD were included. Data were extracted on study design, pharmacology, efficacy outcomes, and safety events. One phase I, 2 phase II, and 6 phase III studies were summarized along with real-world evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Lebrikizumab had dose-dependent reductions in AD severity and pruritus, with improvements observed as early as day 2. Across phase III trials, 33% to 43% of lebrikizumab-treated patients achieved an Investigator\u2019s Global Assessment Score (IGA) 0\/1 compared with 11% or less with placebo. Adverse events were mild; conjunctivitis occurred less frequently than with agents targeting both IL-4 and IL-13.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison to existing drugs:<\/jats:title>\n                    <jats:p>As a selective IL-13 inhibitor, lebrikizumab offers comparable efficacy with reduced ocular adverse events relative to dupilumab. Its pharmacologic distinctions from tralokinumab may carry clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251402987","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:42:07Z","timestamp":1766738527000},"page":"710-714","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7198-2558","authenticated-orcid":false,"given":"Danial","family":"Nasim","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Shaffer","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Drucker AM Wang AR Li WQ Sevetson E Block JK Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. Accessed March 13 2020. www.sciencedirect.com\/science\/article\/pii\/S0022202X16321200","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009864.pub2"},{"key":"e_1_3_2_5_2","unstructured":"LEO Pharma Inc. Adbry (tralokinumab-ldrm) [package insert]. LEO Pharma Inc.; 2024."},{"key":"e_1_3_2_6_2","unstructured":"Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) [package insert]. Regeneron Pharmaceuticals Inc.; 2025."},{"key":"e_1_3_2_7_2","unstructured":"Lebrikizumab (Ebglyss) [package insert]. Eli Lilly and Company; 2025."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00793-5"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.10.016"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02802-3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.01"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01452-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.25251\/SKIN.9.SUPP.515"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.5534"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15326"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00288-x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251402987","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251402987","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251402987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:37:00Z","timestamp":1781516220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251402987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/10600280251402987"],"URL":"https:\/\/doi.org\/10.1177\/10600280251402987","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}